Kenox Pharmaceuticals

Kenox Pharmaceuticals Inc. is an emerging contract development, manufacturing, and testing organisation specialising in innovative aerosol-based drug delivery systems for inhalation, nasal, ophthalmic, and other applications.

With a commitment to accelerating the development of life-changing therapies, Kenox partners with pharmaceutical and biotechnology companies to efficiently bring inhaled and intranasal treatments to the clinic. The company offers extensive expertise in the design, development, manufacturing, and testing of orally inhaled and nasal drug products (OINDPs) and ophthalmic products. Their recent expansion to Good Manufacturing Practice (GMP) facilities enables seamless transition of projects to clinical manufacture and testing of OINDPs for first-in-human (FIH) studies.

Key Products and Services:

Inhalation:

• Nebulisers: Expertise in both established (jet, ultrasound) and advanced (vibrating mesh) platforms. Soft Mist Inhalers (SMIs): Development of SMIs for delivering small molecules and biologics to the lungs.
• Dry Powder Inhalers (DPIs): Comprehensive development and manufacturing across various platforms, including capsule, reservoir, and blister systems.
• Metered Dose Inhalers (MDIs): Formulation and development of MDIs for efficient drug delivery.

Intranasal:

• Unit- & Bi-Dose Systems: Formulation and development for local, nose-to-brain, or systemic applications.
• Multidose Systems: Advanced nasal formulations and drug delivery solutions.

Ophthalmic:

• Soft Mist Sprays and Drops: Development of innovative ophthalmic sprays and drops, translating cutting-edge science into effective eye treatments.

Kenox Pharmaceuticals combines extensive industry experience with agility, ensuring unparalleled project and customer focus. Their team of professionals is dedicated to supporting organisations in bringing innovative therapeutics to patients worldwide.